会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Cancer-associated antigen analogue peptides and uses thereof
    • 癌相关抗原类似物肽及其用途
    • US08404803B2
    • 2013-03-26
    • US11910129
    • 2006-03-31
    • Mitsuo OkuboHiroo MaedaSatoru Takeda
    • Mitsuo OkuboHiroo MaedaSatoru Takeda
    • C07K5/00
    • G01N33/57449A61K38/00A61K39/0011A61K2039/5158C07K14/4727
    • First, to solve the problems of the present invention, the present inventors confirmed the presence of ovarian cancer antigen-specific T cells in the peripheral blood of ovarian cancer patients by using an experimental system that detects combinations of CD4 and IL-4 or IFNγ. Next, using analogue peptides of the core protein MUC 16 of the ovarian cancer-associated antigen CA 125, the present inventors revealed that antigen-specific CD4-positive T cells are present at an average frequency of about 4% in the peripheral mononuclear cells of patients and healthy subjects. Then, the present inventors analyzed the epitope for T cells in the core protein MUC 16 of the ovarian cancer-associated antigen CA 125, and determined the amino acid sequence FTLNFTITN (SEQ ID NO: 1) to be a shorter epitope. The present inventors further discovered that the analogue peptide OVCA11: GHTAPGPLLVPFTLNFTITN (SEQ ID NO:11) is suitable for T cell activation.
    • 首先,为了解决本发明的问题,本发明人通过使用检测CD4和IL-4或IFNγ的组合的实验系统,确认了卵巢癌患者的外周血中卵巢癌抗原特异性T细胞的存在。 接下来,使用卵巢癌相关抗原CA125的核心蛋白MUC16的类似肽,本发明人发现抗原特异性CD4阳性T细胞在外周单核细胞中以约4%的平均频率存在 患者和健康受试者。 然后,本发明人分析了卵巢癌相关抗原CA125的核心蛋白MUC16中的T细胞的表位,并将氨基酸序列FTLNFTITN(SEQ ID NO:1)确定为较短的表位。 本发明人进一步发现,类似物OVCA11:GHTAPGPLLVPFTLNFTITN(SEQ ID NO:11)适用于T细胞活化。